Myriad Genetics Inc (MYGN): John T Henderson , director of Myriad Genetics Inc sold 30,000 shares on Sep 9, 2016. The Insider selling transaction was reported by the company on Sep 13, 2016 to the Securities and Exchange Commission. The shares were sold at $20.36 per share for a total value of $614,816.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 19, 2016, Mark Christopher Capone (CEO) purchased 10,000 shares at $21.24 per share price.On Aug 15, 2016, Ralph L Mcdade (President Myriad RBM, Inc.) purchased 1,000 shares at $21.49 per share price.Also, On Jun 22, 2016, Alexander Ford (President, MGL) sold 18,637 shares at $30.87 per share price.On Apr 8, 2016, Gary A. King (Exec. VP International Ops) sold 15,000 shares at $39.03 per share price.
Myriad Genetics: On Monday, Sep 12, 2016 heightened volatility was witnessed in Myriad Genetics which led to swings in the share price. The shares opened for trading at $20.13 and hit $20.965 on the upside , eventually ending the session at $20.94, with a gain of 3.15% or 0.64 points. The heightened volatility saw the trading volume jump to 1,974,187 shares. The 52-week high of the share price is $46.24 and the company has a market cap of $1,448 M . The 52-week low of the share price is at $19.1.
Company has been under the radar of several Street Analysts.Myriad Genetics is Downgraded by Barclays to Equal Weight while Lowering the Price Target of the company shares to $ 24 from a previous price target of $50 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Aug 10, 2016.Myriad Genetics is Downgraded by Gabelli & Co to Hold while Lowering the Price Target of the company shares to $ 32 from a previous price target of $46 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Aug 10, 2016.Myriad Genetics is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Aug 10, 2016.Myriad Genetics is Downgraded by Piper Jaffray to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Aug 10, 2016.Myriad Genetics is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 22 from a previous price target of $34 . The Rating was issued on Aug 10, 2016.
Myriad Genetics Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics which provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing or assess a patient’s risk of disease progression and disease recurrence and other which provides testing products and services to the pharmaceutical biotechnology and medical research industries research and development and clinical services for patients. It offers diagnostic tests for various diseases such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer and Vectra DA for rheumatoid arthritis.